Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance

Patients with ROS1-rearranged NSCLC demonstrate excellent disease control with ROS1-targeted therapy, but acquired resistance is inevitable. Of particular interest is the ROS1 L2086F kinase domain mutation which is refractory to all currently available ROS1 TKIs apart from cabozantinib. We present a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Mandy, Patil, Tejas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250337/
https://www.ncbi.nlm.nih.gov/pubmed/37291202
http://dx.doi.org/10.1038/s41698-023-00381-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250337/
https://www.ncbi.nlm.nih.gov/pubmed/37291202
http://dx.doi.org/10.1038/s41698-023-00381-0

Ejemplares similares